166 related articles for article (PubMed ID: 22768204)
1. Cellular effects of HER3-specific affibody molecules.
Göstring L; Malm M; Höidén-Guthenberg I; Frejd FY; Ståhl S; Löfblom J; Gedda L
PLoS One; 2012; 7(6):e40023. PubMed ID: 22768204
[TBL] [Abstract][Full Text] [Related]
2. Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway.
Sakai K; Yokote H; Murakami-Murofushi K; Tamura T; Saijo N; Nishio K
Cancer Sci; 2007 Sep; 98(9):1498-503. PubMed ID: 17627612
[TBL] [Abstract][Full Text] [Related]
3. HER2/HER3 regulates extracellular acidification and cell migration through MTK1 (MEKK4).
Sollome JJ; Thavathiru E; Camenisch TD; Vaillancourt RR
Cell Signal; 2014 Jan; 26(1):70-82. PubMed ID: 24036211
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification.
Malm M; Kronqvist N; Lindberg H; Gudmundsdotter L; Bass T; Frejd FY; Höidén-Guthenberg I; Varasteh Z; Orlova A; Tolmachev V; Ståhl S; Löfblom J
PLoS One; 2013; 8(5):e62791. PubMed ID: 23675426
[TBL] [Abstract][Full Text] [Related]
5. A functional comparison between the HER2(high)/HER3 and the HER2(low)/HER3 dimers on heregulin-β1-induced MMP-1 and MMP-9 expression in breast cancer cells.
Kim S; Han J; Shin I; Kil WH; Lee JE; Nam SJ
Exp Mol Med; 2012 Aug; 44(8):473-82. PubMed ID: 22627808
[TBL] [Abstract][Full Text] [Related]
6. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3.
Chen CH; Chernis GA; Hoang VQ; Landgraf R
Proc Natl Acad Sci U S A; 2003 Aug; 100(16):9226-31. PubMed ID: 12874383
[TBL] [Abstract][Full Text] [Related]
8. Effects of silibinin on growth and invasive properties of human ovarian carcinoma cells through suppression of heregulin/HER3 pathway.
Momeny M; Ghasemi R; Valenti G; Miranda M; Zekri A; Zarrinrad G; Javadikooshesh S; Yaghmaie M; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Tumour Biol; 2016 Mar; 37(3):3913-23. PubMed ID: 26482609
[TBL] [Abstract][Full Text] [Related]
9. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
Anido J; Matar P; Albanell J; Guzmán M; Rojo F; Arribas J; Averbuch S; Baselga J
Clin Cancer Res; 2003 Apr; 9(4):1274-83. PubMed ID: 12684395
[TBL] [Abstract][Full Text] [Related]
10. Study of inhibition effect of herceptin on interaction between heregulin and erbB receptors HER3/HER2 by single-molecule force spectroscopy.
Shi X; Xu L; Yu J; Fang X
Exp Cell Res; 2009 Oct; 315(16):2847-55. PubMed ID: 19497323
[TBL] [Abstract][Full Text] [Related]
11. Tea polyphenol (-)-epigallocatechin 3-gallate suppresses heregulin-beta1-induced fatty acid synthase expression in human breast cancer cells by inhibiting phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase cascade signaling.
Pan MH; Lin CC; Lin JK; Chen WJ
J Agric Food Chem; 2007 Jun; 55(13):5030-7. PubMed ID: 17539658
[TBL] [Abstract][Full Text] [Related]
12. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
Kim J; Lee J; Kim C; Choi J; Kim A
Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908
[TBL] [Abstract][Full Text] [Related]
13. Heregulin-induced VEGF expression via the ErbB3 signaling pathway in colon cancer.
Yonezawa M; Wada K; Tatsuguchi A; Akamatsu T; Gudis K; Seo T; Mitsui K; Nagata K; Tanaka S; Fujimori S; Sakamoto C
Digestion; 2009; 80(4):215-25. PubMed ID: 19797898
[TBL] [Abstract][Full Text] [Related]
14. ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells.
Choi BK; Fan X; Deng H; Zhang N; An Z
Cancer Med; 2012 Aug; 1(1):28-38. PubMed ID: 23342251
[TBL] [Abstract][Full Text] [Related]
15. The anti-HER3 antibody in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive gastric cancer.
Wang Q; Zhang X; Shen E; Gao J; Cao F; Wang X; Li Y; Tian T; Wang J; Chen Z; Wang J; Shen L
Cancer Lett; 2016 Sep; 380(1):20-30. PubMed ID: 27317872
[TBL] [Abstract][Full Text] [Related]
16. Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates.
Razumienko EJ; Scollard DA; Reilly RM
J Nucl Med; 2012 Dec; 53(12):1943-50. PubMed ID: 23096164
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.
Brockhoff G; Heiss P; Schlegel J; Hofstaedter F; Knuechel R
Cytometry; 2001 Aug; 44(4):338-48. PubMed ID: 11500850
[TBL] [Abstract][Full Text] [Related]
18. A human epidermal growth factor receptor 3/heregulin interaction inhibitor aptamer discovered using SELEX.
Yokoyama T; Ando T; Iwamoto R; Fuji D; Yamamoto M; Kawakami T
Biochem Biophys Res Commun; 2021 May; 553():148-153. PubMed ID: 33770580
[TBL] [Abstract][Full Text] [Related]
19. Heregulin controls ERα and HER2 signaling in mammospheres of ERα-positive breast cancer cells and interferes with the efficacy of molecular targeted therapy.
Fukui F; Hayashi SI; Yamaguchi Y
J Steroid Biochem Mol Biol; 2020 Jul; 201():105698. PubMed ID: 32404282
[TBL] [Abstract][Full Text] [Related]
20. Distinct characteristics of heregulin signals mediated by HER3 or HER4.
Weiss FU; Wallasch C; Campiglio M; Issing W; Ullrich A
J Cell Physiol; 1997 Nov; 173(2):187-95. PubMed ID: 9365520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
